ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Recommendation of “Buy” from Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been given an average recommendation of “Buy” by the nine ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $78.88.

ANIP has been the topic of a number of recent analyst reports. Guggenheim restated a “buy” rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, April 24th. HC Wainwright initiated coverage on shares of ANI Pharmaceuticals in a research note on Thursday, July 10th. They set a “buy” rating and a $84.00 target price for the company. Finally, Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a research note on Monday, April 21st.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $64.88, for a total transaction of $25,952.00. Following the sale, the vice president owned 78,945 shares of the company’s stock, valued at $5,121,951.60. This represents a 0.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christopher Mutz sold 4,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total transaction of $241,800.00. Following the transaction, the insider directly owned 107,317 shares in the company, valued at $6,487,312.65. The trade was a 3.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,681 shares of company stock valued at $345,222 in the last 90 days. 11.10% of the stock is currently owned by insiders.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds have recently bought and sold shares of ANIP. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals in the first quarter valued at approximately $28,000. US Bancorp DE raised its holdings in shares of ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after purchasing an additional 531 shares during the last quarter. National Bank of Canada FI acquired a new stake in shares of ANI Pharmaceuticals in the first quarter valued at approximately $79,000. GAMMA Investing LLC grew its stake in shares of ANI Pharmaceuticals by 163.8% in the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company’s stock valued at $95,000 after buying an additional 881 shares in the last quarter. Finally, Mesirow Financial Investment Management Inc. bought a new position in shares of ANI Pharmaceuticals in the first quarter valued at $206,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Trading Up 0.4%

Shares of NASDAQ:ANIP opened at $65.19 on Tuesday. The company has a current ratio of 2.66, a quick ratio of 1.98 and a debt-to-equity ratio of 1.46. The company has a 50 day moving average of $63.31 and a 200-day moving average of $62.37. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $77.00. The firm has a market cap of $1.41 billion, a P/E ratio of -51.33 and a beta of 0.57.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 3.12% and a positive return on equity of 21.35%. The business had revenue of $197.12 million for the quarter, compared to the consensus estimate of $179.75 million. During the same period in the previous year, the firm earned $0.82 EPS. The business’s revenue for the quarter was up 43.4% on a year-over-year basis. As a group, analysts anticipate that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.